Suicide fears over weight-loss drug

July 2008
PRWeek (London);7/4/2008, p6
Trade Publication
The article looks at the suicide concerns over the weight-loss drug Acomplia, manufactured by Sanofi-Aventis. The drug has been approved by the British National Institute for Health and Clinical Excellence (NICE) and it is licensed in the Great Britain for the treatment of obese and overweight patients. However, it is found that rimonabant, the drug's compound name, was banned in the U.S. over fears that it can heighten the risk of suicide. Manning Selvage & Lee is the agency that handles public relations (PR) for the drug.


Related Articles

  • NICE needs more rimonabant data.  // GP: General Practitioner;12/14/2007, p3 

    The article reports that the National Institute for Health & Clinical Excellence (NICE) of Great Britain says that Rimonabant should not be used for the treatment of obese and overweight adults. NICE added that more information on how it compares to diet and exercise, orlistat and sibutramine...

  • The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents. Hyeon-Kyu Lee; Eun Bok Choi; Chwang Siek Pak // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p482 

    Since the discovery of rimonabant (Acomplia: 1), a large effort has been directed at the discovery of new, potent and selective CB1R antagonists that serve as anti obesity drugs. As a result, a number of compounds reached various stages of clinical trials by late 2008. However, the announcement...


    The article focuses on a meta-analyis of rimonabant which revealed that the weight-loss drug increases the risk of depression and anxiety and can increase users' suicidal thoughts. The drug targets the endocannabinoid system of the brain, which helps trigger and reward food intake....

  • NICE gives go-ahead for rimonabant.  // Pulse;7/9/2008, Vol. 68 Issue 24, p18 

    The article reports on the approval of the use of rimonabant in obese patients who cannot take orlistat and sibutramine by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. The institute has advised that there must be careful consideration of current or previous...

  • Disappointment at rimonabant halt.  // Independent Nurse;11/3/2008, p4 

    The article reports on clinicians' disappointment on the suspension of the weight-loss drug rimonabant, issued by the European Medicines Agency (EMEA). It is stated that EMEA raised concerns about the risk of psychiatric disorders in patients treated with the drug, and warned no further...

  • NICE dementia row. Hairon, Nerys // Pulse;11/19/2005, Vol. 65 Issue 45, p8 

    The article reports on the warning that the National Institute of Clinical Excellence guidance restricting use of Alzheimer's drugs is harming patients and may cause them to die early in Great Britain. Researchers warned that general practitioners were left to pick up the pieces when patients...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p3 

    The article offers world news brief related to developments in the pharmaceutical industry. Sanofi-Aventis has been told that Acomplia, an obesity pill, has not been recommended for approval by the Food and Drug Administration. The National Institute for Health and Clinical Excellence has...

  • Diagnosing hypertension–implications of the 2011 NICE guidance. Wood, Sally // InnovAiT;Apr2012, Vol. 5 Issue 4, p204 

    The accurate diagnosis of hypertension is a difficult issue. The 2006 National Institute for Health and Clinical Excellence (NICE) guidance for the management of hypertension in adults in primary care recommended the use of clinic measurements taken on multiple occasions. However, this process...

  • Treating early rheumatoid arthritis intensively: current UK practice does not reflect guidelines. Garrood, Toby; Shattles, Warren; Scott, David // Clinical Rheumatology;Jan2011, Vol. 30 Issue 1, p103 

    Recent guidance published in the UK by the National Institute for Health and Clinical Excellence has recommended that patients with early rheumatoid arthritis (RA) are treated with combination disease-modifying anti-rheumatic drugs (DMARDs). It is unclear to what extent this reflects current UK...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics